Influence of Gingival Biotype on the Outcome of Open Flap Debridement (NCT03882138) | Clinical Trial Compass
CompletedNot Applicable
Influence of Gingival Biotype on the Outcome of Open Flap Debridement
India40 participantsStarted 2017-12-01
Plain-language summary
The influence of periodontal thickness has been documented in outcome of various periodontal interventions like non surgical periodontal therapy, mucogingival therapy, guided tissue regeneration (GTR), crown lengthening and implant dentistry. There is lack of study showing the influence of gingival biotype on outcome of surgical procedure. The present study is therefore undertaken to evaluate the influence of gingival biotype on the outcome of open flap debridement for treatment of chronic periodontitis.
Who can participate
Age range
25 Years – 55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Systemically healthy patients with moderate to severe chronic periodontitis
* Age 25-55 years
* Clinical attachment loss(CAL) ≥3 mm
* Probing pocket depth (PPD) ≥5 mm
* Possessing ≥20 natural teeth.
Exclusion Criteria:
* Patients with vertical bone loss
* Current or former smokers or use of tobacco in any form
* Pregnant women, lactating mothers and women taking oral contraceptives
* Patient who had undergone periodontal treatment within 6 months prior to the study
* Patient on anti-inflammatory drugs or antibiotics or history of treatment with medication known to influence periodontal status or healing such as statins, glucocorticoids, phenytoin, calcium channel blockers, immunosuppressants, bisphosphonates or any other host modulatory drug within six months of commencement of study
* Patient with average plaque index ≥1.5 after phase 1 therapy
* Miller Grade II /Grade III tooth mobility after SRP
* Periapical infection in any tooth of the surgical treatment segment.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
clinical attachment level
Timeframe: 6 months
Trial details
NCT IDNCT03882138
SponsorPostgraduate Institute of Dental Sciences Rohtak